| Bioactivity | Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody[1]. |
| Target | Kd: 6.45 nM (SARS-CoV-2 spike protein)IC50: 0.32 nM (spike protein attachment to ACE2) |
| Invitro | Etesevimab (JS016) 与刺突蛋白结合的 Kd 值为 6.45 nM，阻断刺突蛋白附着在人血管紧张素转换酶 2 (ACE2) 受体的 IC50 为 0.32 nM (0.046 μg/mL)[1]。Etesevimab 阻断病毒细胞融合，防止 SARS-CoV-2 入侵人体细胞，并抑制病毒复制[1]。 |
| Name | Etesevimab |
| CAS | 2423948-94-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wu X, et al. Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0035021. |